Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Dec 4, 2023
- Accession no.
- 0001209191-23-057328
- Filed
- Dec 4, 2023, 8:33 PM ET
- Trade date
- Aug 25-Nov 30, 2023
- Filing delay
- 101 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market purchases total $2.02K. It was filed 101 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001209191-24-000442 (Jan 3, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +1,365 | $0.21 | +$286.65 | 37,100 | Indirect | |
| Aug 31, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +900 | $0.15 | +$135 | 43,100 | Indirect | |
| Nov 14, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +132 | $0.12 | +$15.84 | 44,200 | Indirect | |
| Nov 28, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +1,470 | $0.12F1 | +$176.4 | 299,724 | Direct | |
| Nov 29, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +4,325 | $0.12F2 | +$519 | 335,724 | Direct | |
| Nov 30, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +7,417 | $0.12F3 | +$890.04 | 395,124 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive.
Referenced by the price of 1 transaction in Table I.